What is gene-editing technology?

Gene-editing technology refers to techniques that allow scientists to modify an organism's DNA. This can lead to advancements in medicine, agriculture, and biotechnology by enabling precise changes to genetic material.

What is Crispr technology?

Crispr technology is a revolutionary gene-editing tool that enables precise modifications to DNA. It allows for targeted changes in the genetic code, which can lead to advancements in genetic research and therapy.

What is commercialization in biotechnology?

Commercialization in biotechnology refers to the process of bringing biotechnological innovations and products to market. This includes development, marketing, and sales of biotech products to generate profit.

What is the significance of a $555 million deal?

A $555 million deal signifies a substantial investment and commitment to a partnership or project. In the context of biotechnology, it reflects confidence in the potential of the technology involved.

Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Finance > AstraZeneca inks $555 million gene-editing technology deal with Algen, FT reports

Finance

AstraZeneca inks $555 million gene-editing technology deal with Algen, FT reports

Published by Global Banking & Finance Review®

Posted on October 6, 2025

1 min read

Last updated: January 21, 2026

AstraZeneca inks $555 million gene-editing technology deal with Algen, FT reports - Finance news and analysis from Global Banking & Finance Review

AstraZeneca inks $555 million gene-editing technology deal with Algen, FT reports

Quick Summary

AstraZeneca Secures $555 Million Deal for Gene-Editing Technology

AstraZeneca's Strategic Partnership with Algen

Details of the Agreement

Implications for Gene-Editing Therapies

Key Takeaways

Frequently Asked Questions about AstraZeneca inks $555 million gene-editing technology deal with Algen, FT reports